322 related articles for article (PubMed ID: 21248270)
1. Recent developments in cancer vaccines.
Palucka K; Ueno H; Banchereau J
J Immunol; 2011 Feb; 186(3):1325-31. PubMed ID: 21248270
[TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
3. Human dendritic cell subsets for vaccination.
Dubsky P; Ueno H; Piqueras B; Connolly J; Banchereau J; Palucka AK
J Clin Immunol; 2005 Nov; 25(6):551-72. PubMed ID: 16380819
[TBL] [Abstract][Full Text] [Related]
4. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
5. Building on dendritic cell subsets to improve cancer vaccines.
Palucka K; Ueno H; Zurawski G; Fay J; Banchereau J
Curr Opin Immunol; 2010 Apr; 22(2):258-63. PubMed ID: 20226644
[TBL] [Abstract][Full Text] [Related]
6. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
7. DC-based cancer vaccines.
Gilboa E
J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349
[TBL] [Abstract][Full Text] [Related]
8. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
9. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
10. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
11. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
12. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
14. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
Altin JG; van Broekhoven CL; Parish CR
Expert Opin Biol Ther; 2004 Nov; 4(11):1735-47. PubMed ID: 15500402
[TBL] [Abstract][Full Text] [Related]
15. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy by fusions of dendritic cells and tumor cells.
Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H
Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in cancer immunotherapy.
Schuler G
Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells: are they clinically relevant?
Palucka K; Ueno H; Roberts L; Fay J; Banchereau J
Cancer J; 2010; 16(4):318-24. PubMed ID: 20693842
[TBL] [Abstract][Full Text] [Related]
20. Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors.
Porchia BFMM; Moreno ACR; Ramos RN; Diniz MO; de Andrade LHTM; Rosa DS; Barbuto JAM; Boscardin SB; Ferreira LCS
Mol Cancer Ther; 2017 Sep; 16(9):1922-1933. PubMed ID: 28522585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
